Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.60 |
| ▸ | IDO1 | P14902 | 2/20 | 0.60 |
| ▸ | AGXT | P21549 | 2/20 | 0.60 |
| ▸ | CMA1 | P23946 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | LPO | P22079 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL833882 | 0.83 | TAAR1 (0.67) | TAAR1IDO1AGXTCMA1CHRM2 | |
| SCHEMBL7638048 | 0.83 | TAAR1 (0.60) | TAAR1IDO1AGXTCMA1CHRM2 | |
| SCHEMBL723511 | 0.82 | TAAR1 (0.77) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL30080050 | 0.82 | TAAR1 (0.77) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL2099512 | 0.82 | CHRM2 (0.66) | TAAR1IDO1AGXTCMA1CHRM2 | |
| SCHEMBL6205291 | 0.80 | IDO1 (0.62) | TAAR1IDO1AGXTCMA1CHRM2 | |
| SCHEMBL10607028 | 0.80 | CHRM2 (0.63) | TAAR1IDO1AGXTCMA1CHRM2 | |
| SCHEMBL29908907 | 0.80 | TAAR1 (0.62) | TAAR1IDO1AGXTCMA1CHRM2 | |
| SCHEMBL12497 | 0.80 | TAAR1 (0.62) | TAAR1IDO1AGXTCMA1CHRM2 | |
| SCHEMBL27583382 | 0.80 | TAAR1 (0.62) | TAAR1IDO1AGXTCMA1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. | 2024-05-16 | — | — | US | claimed |
| WO-2024054832-A1 | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | claimed |
| CN-107629020-B | 4H-1,2, 4-oxadiazine-5 (6H) -ketone compound and synthetic method thereof | 湖北科技学院 | 2020-09-04 | — | — | CN | claimed |
| CN-107176925-B | Synthesis method of polysubstituted imidazoline-2, 4-diketone compound | 湖北科技学院 | 2020-04-28 | — | — | CN | claimed |
| CN-107522656-A | One kind 3（4 methoxyphenyls）The synthetic method of the bromoquinoline of 6 methoxyl group, 4 chlorine 5,7 2 | 南京大学 | 2017-12-29 | — | — | CN | claimed |
| CN-107501174-A | A kind of synthetic method of quinoline | 广州大学 | 2017-12-22 | — | — | CN | claimed |
| CN-107501175-A | A kind of synthetic method of quinoline | 广州大学 | 2017-12-22 | — | — | CN | claimed |
| CN-107459481-A | One kind 3（4 methoxyphenyls）The synthetic method of the bromoquinoline of 6 methoxyl group, 4 chlorine 5,7 2 | 广州大学 | 2017-12-12 | — | — | CN | claimed |
| CN-107417611-A | One kind 3（4 methoxyphenyls）The synthetic method of the bromoquinoline of 6 methoxyl group, 4 chlorine 5,7 2 | 广州大学 | 2017-12-01 | — | — | CN | claimed |
| CN-107417612-A | A kind of synthetic method of quinoline | 广州大学 | 2017-12-01 | — | — | CN | claimed |
| WO-2005112640-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2005-12-01 | — | — | WO | claimed |
| EP-1581207-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2005-10-05 | — | — | EP | claimed |
| EP-0873519-A4 | HIV PROTEASE INHIBITORS | SCRIPPS RESEARCH INST (US) | 2005-04-27 | — | — | EP | claimed |
| CN-1589268-A | Substituted benzopyrans as selective estrogen receptor-beta agonists | LILLY CO ELI (US) | 2005-03-02 | — | — | CN | claimed |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED | 2004-08-19 | — | — | US | claimed |
| WO-2004041201-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-05-21 | — | — | WO | claimed |
| JP-2000502332-A | — | — | 2000-02-29 | — | — | JP | claimed |
| EP-0873519-A1 | HIV PROTEASE INHIBITORS | The Scripps Research Institute (US) | 1998-10-28 | — | — | EP | claimed |
| WO-1997021100-A9 | HIV PROTEASE INHIBITORS | — | 1997-10-30 | — | — | WO | claimed |
| WO-1997021100-A1 | HIV PROTEASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-06-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | CKS1B, CKS2, MARK1 | TAAR1 3944/4885IDO1 1901/4885AGXT 1556/4885 |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | BBOX1, HAVCR2, CYP2E1 | TAAR1 4151/4885IDO1 2220/4885AGXT 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.